Pyridostigmine Bromide is a drug owned by Amneal Pharmaceuticals Llc. It is protected by 8 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 18, 2038. Details of Pyridostigmine Bromide's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11478425 | Extended release compositions comprising pyridostigmine |
Jun, 2038
(13 years from now) | Active |
| US12042559 | Gastroretentive dosage forms for sustained drug delivery |
Jun, 2038
(13 years from now) | Active |
| US10925833 | Extended release compositions comprising pyridostigmine |
Jun, 2038
(13 years from now) | Active |
| US10987311 | Extended release compositions comprising pyridostigmine |
Jun, 2038
(13 years from now) | Active |
| US10881617 | Extended release compositions comprising pyridostigmine |
Jun, 2038
(13 years from now) | Active |
| US11666536 | Extended release compositions comprising pyridostigmine |
Jun, 2038
(13 years from now) | Active |
| US11911515 | Extended release compositions comprising pyridostigmine |
Jun, 2038
(13 years from now) | Active |
| US11229606 | Extended release compositions comprising pyridostigmine |
Jun, 2038
(13 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Pyridostigmine Bromide is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Pyridostigmine Bromide's family patents as well as insights into ongoing legal events on those patents.
Pyridostigmine Bromide's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Pyridostigmine Bromide's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 18, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Pyridostigmine Bromide Generic API suppliers:
Pyridostigmine Bromide is the generic name for the brand Pyridostigmine Bromide. 12 different companies have already filed for the generic of Pyridostigmine Bromide, with Impax Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Pyridostigmine Bromide's generic
About Pyridostigmine Bromide
Pyridostigmine Bromide is a drug owned by Amneal Pharmaceuticals Llc. Pyridostigmine Bromide uses Pyridostigmine Bromide as an active ingredient. Pyridostigmine Bromide was launched by Amneal in 2024.
Approval Date:
Pyridostigmine Bromide was approved by FDA for market use on 04 October, 2024.
Active Ingredient:
Pyridostigmine Bromide uses Pyridostigmine Bromide as the active ingredient. Check out other Drugs and Companies using Pyridostigmine Bromide ingredient
Dosage:
Pyridostigmine Bromide is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 105MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |